Aug 6 (Reuters) – Britain’s Hikma Pharmaceuticals reported a 9% rise in half-year core-operating profit and maintained its annual outlook on Thursday, supported by the generic drugmaker’s turnaround efforts to expand its product base and streamline manufacturing.
Its shares rose about 5% in early trading.
The company, which sells its own-branded and licensed products in key North America, Middle East and North Africa markets, was forced to scrap its medium-term targets in February due to challenges at one of its divisions, and manufacturing delays in the United States.
Hikma said it was well positioned to support efforts to strengthen its U.S. supply chain, noting that the majority of the medicines it sold in the country were manufactured in Ohio and New Jersey. The drugmaker said it would continue to engage constructively with the U.S. administration.
Potential U.S. tariffs on generic drug imports are aimed at boosting domestic manufacturing.
“We have made good progress against our strategic priorities in the first half of 2026, launching new products, strengthening our pipeline, signing new partnerships and optimising our manufacturing operations,” said CEO Said Darwazah, who has been tasked with the drugmaker’s turnaround.
(Reporting by Simone Lobo in Bengaluru; Editing by Sherry Jacob-Phillips and Mrigank Dhaniwala)
